Nephrol Dial Transplant (1999) 14: 1853-1860
© 1999 European Renal Association-European Dialysis and Transplant Association
Molecular Basis of Renal Disease
`The growth hormone–insulin-like growth factor axis in kidney re-revisited
George M. O'Brien Kidney and Urological Diseases Center, Renal Division, Department of Internal Medicine and Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO, USA
Correspondence and offprint requests to: Marc R. Hammerman, MD, Renal Division Box 8126, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110, USA.
Keywords: acute renal failure; chronic renal failure; growth hormone; insulin-like growth factor I; metanephros; transplantation
Introduction
We published comprehensive reviews on the renal growth hormone (GH)–insulin-like growth factor (IGF) axis in 1989 [1] and 1993 [2]. These reviews summarized what was known concerning the synthesis of IGF I, and IGF-binding proteins in kidney, and the roles of GH and IGF I as regulators of renal development, growth and function. During the years since 1993, a good deal of additional information about the GH–IGF I axis in kidney has been provided by a number of laboratories. Much of this work has been catalogued and discussed elsewhere [3–6].
New insights have been gained into the role that IGF I plays in renal organogenesis [7,8], and relating to novel uses for IGF I to promote kidney development. Several clinical studies have tested the efficacy of IGF I in humans as a therapy to prevent the development of
IGF I and kidney development
Metanephric organ culture
IGF I-/- transgenic mice
IGF I and metanephric transplantation
IGF I and acute renal failure
IGF I, ischaemia and compensatory renal growth
GH, IGF I and chronic renal failure
Summary and conclusions
Acknowledgments
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. H. Little Regrow or Repair: Potential Regenerative Therapies for the Kidney J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2390 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ruggenenti, C. Flores, C. Aros, B. Ene-Iordache, R. Trevisan, C. Ottomano, and G. Remuzzi Renal and Metabolic Effects of Insulin Lispro in Type 2 Diabetic Subjects With Overt Nephropathy Diabetes Care, February 1, 2003; 26(2): 502 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Charmandari, C G D Brook, and P C Hindmarsh Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? Arch. Dis. Child., April 1, 2002; 86(4): 266 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Flores-Morales, N. Stahlberg, P. Tollet-Egnell, J. Lundeberg, R. L. Malek, J. Quackenbush, N. H. Lee, and G. Norstedt Microarray Analysis of the in Vivo Effects of Hypophysectomy and Growth Hormone Treatment on Gene Expression in the Rat Endocrinology, July 1, 2001; 142(7): 3163 - 3176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Charmandari, P. C. Hindmarsh, A. Johnston, and C. G. D. Brook Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Alterations in Cortisol Pharmacokinetics at Puberty J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2701 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. ROELFSEMA and R. G. CLARK The Growth Hormone and Insulin-Like Growth Factor Axis: Its Manipulation for the Benefit of Growth Disorders in Renal Failure J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1297 - 1306. [Abstract] [Full Text]
|
|